Cargando…

The Comparison of Two Challenging Low Dose APIs in a Continuous Direct Compression Process

Segregation is a common problem in batch-based direct compression (BDC) processes, especially with low-dose tablet products, as is the preparation of a homogenous mixture. The scope of the current work was to explore if a continuous direct compression (CDC) process could serve as a solution for thes...

Descripción completa

Detalles Bibliográficos
Autores principales: Ervasti, Tuomas, Niinikoski, Hannes, Mäki-Lohiluoma, Eero, Leppinen, Heidi, Ketolainen, Jarkko, Korhonen, Ossi, Lakio, Satu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7151305/
https://www.ncbi.nlm.nih.gov/pubmed/32244950
http://dx.doi.org/10.3390/pharmaceutics12030279
_version_ 1783521219970072576
author Ervasti, Tuomas
Niinikoski, Hannes
Mäki-Lohiluoma, Eero
Leppinen, Heidi
Ketolainen, Jarkko
Korhonen, Ossi
Lakio, Satu
author_facet Ervasti, Tuomas
Niinikoski, Hannes
Mäki-Lohiluoma, Eero
Leppinen, Heidi
Ketolainen, Jarkko
Korhonen, Ossi
Lakio, Satu
author_sort Ervasti, Tuomas
collection PubMed
description Segregation is a common problem in batch-based direct compression (BDC) processes, especially with low-dose tablet products, as is the preparation of a homogenous mixture. The scope of the current work was to explore if a continuous direct compression (CDC) process could serve as a solution for these challenges. Furthermore, the principle of a platform formulation was demonstrated for low dose tablets. The combination of filler excipients and the API in the formulation used was suitable for direct compression, but also prone to induce segregation in BDC process. The CDC process was found to be very promising; it was shown that tablets with the desired quality parameters could be manufactured successfully with both of the APIs studied. Powder analysis indicated that the APIs display some fundamental differences in their physical properties, which was also reflected in powder mixture properties and, hence, eventually in processing. However, process parameters, especially mixer impeller speed, were not found to have any significant influence on end product quality. The study suggests that a CDC process can be a viable solution to resolve the challenges described. Moreover, manufacturing by using a universal platform formulation seems to be a feasible way for producing low-dose tablets.
format Online
Article
Text
id pubmed-7151305
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-71513052020-04-20 The Comparison of Two Challenging Low Dose APIs in a Continuous Direct Compression Process Ervasti, Tuomas Niinikoski, Hannes Mäki-Lohiluoma, Eero Leppinen, Heidi Ketolainen, Jarkko Korhonen, Ossi Lakio, Satu Pharmaceutics Article Segregation is a common problem in batch-based direct compression (BDC) processes, especially with low-dose tablet products, as is the preparation of a homogenous mixture. The scope of the current work was to explore if a continuous direct compression (CDC) process could serve as a solution for these challenges. Furthermore, the principle of a platform formulation was demonstrated for low dose tablets. The combination of filler excipients and the API in the formulation used was suitable for direct compression, but also prone to induce segregation in BDC process. The CDC process was found to be very promising; it was shown that tablets with the desired quality parameters could be manufactured successfully with both of the APIs studied. Powder analysis indicated that the APIs display some fundamental differences in their physical properties, which was also reflected in powder mixture properties and, hence, eventually in processing. However, process parameters, especially mixer impeller speed, were not found to have any significant influence on end product quality. The study suggests that a CDC process can be a viable solution to resolve the challenges described. Moreover, manufacturing by using a universal platform formulation seems to be a feasible way for producing low-dose tablets. MDPI 2020-03-20 /pmc/articles/PMC7151305/ /pubmed/32244950 http://dx.doi.org/10.3390/pharmaceutics12030279 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ervasti, Tuomas
Niinikoski, Hannes
Mäki-Lohiluoma, Eero
Leppinen, Heidi
Ketolainen, Jarkko
Korhonen, Ossi
Lakio, Satu
The Comparison of Two Challenging Low Dose APIs in a Continuous Direct Compression Process
title The Comparison of Two Challenging Low Dose APIs in a Continuous Direct Compression Process
title_full The Comparison of Two Challenging Low Dose APIs in a Continuous Direct Compression Process
title_fullStr The Comparison of Two Challenging Low Dose APIs in a Continuous Direct Compression Process
title_full_unstemmed The Comparison of Two Challenging Low Dose APIs in a Continuous Direct Compression Process
title_short The Comparison of Two Challenging Low Dose APIs in a Continuous Direct Compression Process
title_sort comparison of two challenging low dose apis in a continuous direct compression process
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7151305/
https://www.ncbi.nlm.nih.gov/pubmed/32244950
http://dx.doi.org/10.3390/pharmaceutics12030279
work_keys_str_mv AT ervastituomas thecomparisonoftwochallenginglowdoseapisinacontinuousdirectcompressionprocess
AT niinikoskihannes thecomparisonoftwochallenginglowdoseapisinacontinuousdirectcompressionprocess
AT makilohiluomaeero thecomparisonoftwochallenginglowdoseapisinacontinuousdirectcompressionprocess
AT leppinenheidi thecomparisonoftwochallenginglowdoseapisinacontinuousdirectcompressionprocess
AT ketolainenjarkko thecomparisonoftwochallenginglowdoseapisinacontinuousdirectcompressionprocess
AT korhonenossi thecomparisonoftwochallenginglowdoseapisinacontinuousdirectcompressionprocess
AT lakiosatu thecomparisonoftwochallenginglowdoseapisinacontinuousdirectcompressionprocess
AT ervastituomas comparisonoftwochallenginglowdoseapisinacontinuousdirectcompressionprocess
AT niinikoskihannes comparisonoftwochallenginglowdoseapisinacontinuousdirectcompressionprocess
AT makilohiluomaeero comparisonoftwochallenginglowdoseapisinacontinuousdirectcompressionprocess
AT leppinenheidi comparisonoftwochallenginglowdoseapisinacontinuousdirectcompressionprocess
AT ketolainenjarkko comparisonoftwochallenginglowdoseapisinacontinuousdirectcompressionprocess
AT korhonenossi comparisonoftwochallenginglowdoseapisinacontinuousdirectcompressionprocess
AT lakiosatu comparisonoftwochallenginglowdoseapisinacontinuousdirectcompressionprocess